All of the following statements are true about tumor suppressor gene TP53, except?
All of the following are angiogenic factors EXCEPT?
What is the most common mutation associated with male breast carcinoma?
What is the most important indicator of malignancy in smooth muscle tumors?
Tubular (Canalicular) adenoma most commonly occurs on which of the following locations?
Migratory thrombophlebitis is a classic paraneoplastic syndrome associated with which type of malignancy?
Which of the following is not a risk factor for transitional cell carcinoma of the urinary bladder?
What are the characteristic margins of squamous cell carcinoma?
Melanoma is:
Deletion of chromosome 11 leads to which of the following conditions?
Explanation: **Explanation** The **TP53 gene**, located on chromosome 17p13.1, is known as the "Guardian of the Genome." [1] It acts as a molecular sentry that monitors cellular stress, particularly DNA damage. **Why Option C is the correct answer (The False Statement):** When a cell is exposed to DNA-damaging agents like **UV irradiation**, ionizing radiation, or mutagenic chemicals, the levels of p53 protein **increase** (not decrease). This occurs because DNA damage triggers kinases (like ATM) that phosphorylate p53, preventing its degradation by MDM2. The accumulated p53 then acts as a transcription factor to **arrest the cell cycle** (at the G1/S checkpoint) to allow for DNA repair, rather than stimulating it [1]. **Analysis of other options:** * **Option A:** p53 regulates the cell cycle primarily by transcribing **p21** (a CDK inhibitor), which inhibits Cyclin E/CDK2 complexes, preventing the cell from entering the S-phase [1]. * **Option B:** If DNA damage is irreparable, p53 induces **apoptosis** by upregulating pro-apoptotic genes like **BAX** and PUMA [1]. * **Option D:** Germline (inherited) mutations of TP53 result in **Li-Fraumeni Syndrome**, characterized by a 25-fold increased risk of developing various tumors (sarcomas, breast cancer, leukemia, and adrenocortical carcinoma) at a young age. **High-Yield Clinical Pearls for NEET-PG:** * **Most common genetic alteration** in human cancer: TP53 mutation (>50% of all cancers) [1]. * **MDM2:** The negative regulator of p53; it targets p53 for degradation via the ubiquitin-proteasome pathway. * **Quiescence:** Temporary cell cycle arrest induced by p53 [1]. * **Senescence:** Permanent cell cycle arrest induced by p53 [1]. * **HPV E6 protein:** Binds to and facilitates the degradation of p53 (relevant in cervical cancer). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 301-304.
Explanation: **Explanation:** Angiogenesis (neovascularization) is a critical step in tumor growth and metastasis, regulated by a balance between pro-angiogenic and anti-angiogenic factors [2]. **Why IFN is the correct answer:** **Interferons (especially IFN-α and IFN-β)** are potent **inhibitors of angiogenesis**. They function by downregulating the production of pro-angiogenic proteins like bFGF and VEGF. Clinically, IFN-α is sometimes used in the treatment of vascular tumors like infantile hemangiomas because of its angiostatic properties. **Analysis of incorrect options:** * **VEGF (Vascular Endothelial Growth Factor):** The most important and potent pro-angiogenic factor. It stimulates endothelial cell proliferation, migration, and increased vascular permeability [1]. * **PDGF (Platelet-Derived Growth Factor):** Promotes angiogenesis by recruiting pericytes and smooth muscle cells to stabilize newly formed vessels [1], [3]. * **TGF-β (Transforming Growth Factor-beta):** While complex, TGF-β generally acts as a pro-angiogenic factor in the tumor microenvironment by stimulating the production of VEGF and promoting the maturation of the extracellular matrix [1]. **High-Yield NEET-PG Pearls:** * **The "Angiogenic Switch":** Tumors remain small (1-2 mm) until they switch to an angiogenic phenotype, often triggered by hypoxia via **HIF-1α (Hypoxia-Inducible Factor 1α)** [2]. * **Other Pro-angiogenic factors:** bFGF (basic Fibroblast Growth Factor), Angiopoietins, and IL-8 [1], [2]. * **Other Anti-angiogenic factors:** **Thrombospondin-1** (p53-induced), **Angiostatin** (plasminogen fragment), and **Endostatin** (collagen XVIII fragment) [2]. * **VHL Gene:** Loss of VHL leads to constitutive activation of HIF-1α, causing high levels of VEGF (seen in Von Hippel-Lindau syndrome and Renal Cell Carcinoma). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 115-116. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 313-314. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. With Illustrations By, pp. 31-32.
Explanation: **Explanation:** **1. Why BRCA 2 is Correct:** While male breast cancer is rare (accounting for <1% of all breast cancers), genetic predisposition plays a significant role. Mutations in the **BRCA 2** gene on chromosome 13q12 are the most common genetic risk factor [1]. Men with a BRCA 2 mutation have a cumulative lifetime risk of approximately **6-7%** for developing breast cancer, which is significantly higher than the general male population. **2. Why Other Options are Incorrect:** * **BRCA 1:** While strongly associated with female breast and ovarian cancer, BRCA 1 mutations are much less frequently associated with male breast cancer compared to BRCA 2 [1]. * **p53:** Mutations in the TP53 gene (Li-Fraumeni Syndrome) increase the risk of various malignancies, including breast cancer, but it is not the *most common* specific mutation identified in male breast cancer cohorts [2]. * **CDH 1:** This gene encodes E-cadherin. Mutations are primarily associated with **Hereditary Diffuse Gastric Cancer** and **Lobular Carcinoma** of the breast in females. Male breast cancer is almost exclusively of the **Infiltrating Ductal** type, making CDH 1 mutations irrelevant here. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** The strongest risk factor for male breast cancer is **Klinefelter Syndrome (47, XXY)**, which increases risk by 20-50 times. Other factors include hyperestrogenism (cirrhosis, obesity) and radiation exposure. * **Histology:** The most common histological subtype in men is **Infiltrating Ductal Carcinoma**. Lobular carcinoma is extremely rare because the male breast lacks developed lobules [3]. * **Molecular Profile:** Male breast cancers are more likely to be **ER/PR positive** compared to female breast cancers. * **Presentation:** Usually presents as a subareolar mass with nipple discharge or skin tethering. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1058-1059. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1059-1060. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1054-1056.
Explanation: In the evaluation of smooth muscle tumors (Leiomyoma vs. Leiomyosarcoma), the distinction between benign and malignant is based on a constellation of histological features. [1] **Why Mitotic Index is the Correct Answer:** The **mitotic index** (number of mitoses per 10 High Power Fields) is the most reliable and objective indicator of malignancy. For uterine smooth muscle tumors, a mitotic count of **>10 mitoses per 10 HPF** is generally diagnostic of Leiomyosarcoma, even in the absence of other features. [1] If cellular atypia or necrosis is present, the threshold for the mitotic index required to diagnose malignancy decreases (usually >5 mitoses per 10 HPF). **Explanation of Incorrect Options:** * **B. Atypia:** While nuclear pleomorphism and atypia are common in malignancies, they can be seen in benign variants like "Symplastic Leiomyoma" (Bizarre Leiomyoma). Thus, atypia alone is not definitive. * **C. Necrosis:** Specifically, **Coagulative Tumor Cell Necrosis** is a strong indicator of malignancy. [1] However, simple hyaline or infarct-type necrosis is common in benign leiomyomas due to rapid growth or torsion. * **D. Cellularity:** Increased cellularity is seen in "Cellular Leiomyomas," which remain benign despite being more densely packed than the surrounding myometrium. **High-Yield NEET-PG Pearls:** * **The Triad of Malignancy:** Diagnosis of Leiomyosarcoma usually requires at least two of the following: (1) High mitotic index, (2) Diffuse nuclear atypia, and (3) Coagulative tumor cell necrosis. [1] * **Origin:** Unlike many other cancers, Leiomyosarcomas typically arise **de novo** and NOT from pre-existing leiomyomas. * **Epidemiology:** They are most common in postmenopausal women, whereas leiomyomas are estrogen-dependent and common in the reproductive age group. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1024-1025.
Explanation: **Explanation:** **Canalicular Adenoma** (formerly known as Tubular Adenoma) is a benign salivary gland neoplasm that arises almost exclusively from the minor salivary glands. 1. **Why Upper Lip is Correct:** The **upper lip** is the most common site for Canalicular Adenoma, accounting for nearly **70-80% of all cases**. It typically presents as a slow-growing, painless, firm, or fluctuant submucosal nodule in older adults (peak incidence in the 7th decade). Histologically, it is characterized by "beaded" cords of columnar or cuboidal epithelium forming long canals (canaliculi). 2. **Analysis of Incorrect Options:** * **B. Palate:** While the palate is the most common site for most other minor salivary gland tumors (like Pleomorphic Adenoma or Mucoepidermoid Carcinoma), it is the second most common site for Canalicular Adenoma, trailing significantly behind the upper lip. * **C. Lower Lip:** This is a classic "distractor." While **Mucocele** is extremely common on the lower lip [1], salivary gland *neoplasms* (both benign and malignant) are rare here. A tumor on the upper lip is more likely to be benign (Canalicular Adenoma), whereas a tumor on the lower lip has a higher statistical probability of being malignant. * **D. Gingiva:** This is an infrequent site for minor salivary gland tumors compared to the buccal mucosa or palate. **High-Yield Clinical Pearls for NEET-PG:** * **Rule of Thumb:** If a salivary gland tumor is on the **upper lip**, think **Canalicular Adenoma**. If it is on the **lower lip**, think **Mucocele** (non-neoplastic) [1] or suspect malignancy. * **Monomorphic Adenoma:** Canalicular adenoma belongs to the group of monomorphic adenomas (composed of a single cell type), unlike Pleomorphic Adenoma which has mixed components. * **Demographics:** Shows a strong predilection for females and the elderly. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, pp. 750-751.
Explanation: **Explanation:** **Migratory thrombophlebitis**, also known as **Trousseau sign of malignancy**, is a classic paraneoplastic syndrome characterized by recurrent episodes of vessel inflammation and clot formation that "migrate" from one site to another [1]. **Why Pancreatic Cancer is correct:** The association is strongest with **adenocarcinomas**, particularly **pancreatic cancer** (especially of the body and tail). The underlying mechanism involves the release of **procoagulants** (such as mucins) and tissue factor from the tumor cells [1]. These substances activate the coagulation cascade and trigger platelet aggregation, leading to spontaneous venous thrombosis in superficial and deep veins. **Analysis of Incorrect Options:** * **Bladder Cancer:** While advanced bladder cancer can be prothrombotic, it is not classically associated with the "migratory" pattern of thrombophlebitis. * **Breast Cancer:** Breast cancer is more frequently associated with paraneoplastic syndromes like hypercalcemia (via PTHrP) or dermatomyositis, rather than Trousseau sign. * **Liver Cancer (HCC):** Hepatocellular carcinoma is more commonly linked to paraneoplastic erythrocytosis (due to EPO production) or hypoglycemia. **NEET-PG High-Yield Pearls:** * **Trousseau Sign:** Do not confuse this with the "Trousseau sign of latent tetany" (carpal spasm induced by BP cuff inflation in hypocalcemia). * **Hypercoagulability in Malignancy:** This is often referred to as a "chronic DIC" state [1]. * **Common Association:** If pancreatic cancer is not in the options, look for **Lung Cancer** (Adenocarcinoma), as it is the second most common association. * **Clinical Presentation:** Patients present with tender, erythematous, linear cords on the extremities that resolve in one area only to reappear in another [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 522-523.
Explanation: **Explanation:** The correct answer is **None of the above** because all three options listed (Smoking, Schistosomiasis, and Aniline dyes) are established risk factors for the development of bladder cancer [1]. 1. **Smoking (Option A):** This is the **most significant risk factor** for Transitional Cell Carcinoma (TCC), also known as Urothelial Carcinoma [1]. Cigarette smoke contains naphthylamine and polycyclic aromatic hydrocarbons which are excreted in urine and act as direct carcinogens on the urothelium. 2. **Schistosomiasis (Option B):** Infection with *Schistosoma haematobium* is a major risk factor. While it is most classically associated with **Squamous Cell Carcinoma (SCC)** due to chronic irritation and squamous metaplasia, it also significantly increases the overall risk of **Transitional Cell Carcinoma** in endemic areas [1]. 3. **Aniline Dyes (Option C):** Occupational exposure to aromatic amines (found in rubber, chemical, and leather industries) is a classic high-yield risk factor [1]. Specifically, **2-naphthylamine** and benzidine are potent urothelial carcinogens. **Clinical Pearls for NEET-PG:** * **Most common type:** In the developed world, TCC is the most common bladder cancer (>90%). * **Classic Presentation:** Painless gross hematuria in an elderly male. * **Cyclophosphamide:** This chemotherapy agent is a known risk factor for TCC; the risk can be mitigated by administering **MESNA**. * **Field Cancerization:** This concept explains why TCC is often multifocal; the entire urothelial lining is exposed to the same urinary carcinogens, leading to multiple independent primary tumors. * **Phenacetin:** Long-term use of this analgesic (now largely banned) is also a documented risk factor. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 968-970.
Explanation: **Explanation:** The characteristic margin of **Squamous Cell Carcinoma (SCC)** is **everted (turned outward)**. This occurs because the malignant epithelial cells at the edge of the ulcer undergo rapid, uncontrolled proliferation [1]. This excessive growth at the periphery causes the edges to spill over the surrounding normal skin, creating a "heaped-up" or cauliflower-like appearance [2]. **Analysis of Options:** * **Everted (Correct):** Typical of rapidly growing malignant epithelial tumors like SCC [1]. The exuberant growth of neoplastic cells at the margins pushes the edges outward. * **Rolled (Incorrect):** This is the hallmark of **Basal Cell Carcinoma (BCC)**. The margins appear pearly, translucent, and beaded due to the slow, radial spread of tumor nests beneath the epidermis. * **Undermined (Incorrect):** Characteristic of **Tuberculosis (TB) ulcers**. The infection destroys the subcutaneous tissue faster than the overlying skin, leaving the edges hanging over the ulcer base. * **Inverted (Incorrect):** These margins are seen in **Trophic ulcers** (e.g., pressure sores or diabetic ulcers), where there is a lack of healing and the edges punch inward. **High-Yield Clinical Pearls for NEET-PG:** * **SCC Histology:** Look for "Keratin pearls" and "Intercellular bridges" (desmosomes) [1]. * **Precursor Lesions:** Actinic keratosis and Bowen’s disease are common precursors [1]. * **Marjolin’s Ulcer:** A specific type of SCC arising in chronic scars or long-standing burn wounds; it is notoriously aggressive [1]. * **Punch-out edges:** Classically seen in **Syphilitic (gummatous) ulcers**. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 643-645. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, p. 1158.
Explanation: **Explanation:** **1. Why the Correct Answer is Right:** Melanoma is a highly aggressive **malignant neoplasm** arising from **melanocytes**, which are neuroectoderm-derived cells responsible for melanin production [1]. While most commonly found in the **skin**, melanocytes are also present in the **mucous membranes** (oral, genital, anorectal), the uveal tract of the eye, and the leptomeninges. Therefore, melanoma is defined as a malignancy of these tissues. **2. Why the Other Options are Wrong:** * **Options A & D (Benign):** Despite the suffix "-oma" (which usually denotes benign tumors like lipoma or adenoma), melanoma is a classic exception [1]. It is inherently malignant. Other "malignant -omas" high-yield for NEET-PG include Lymphoma, Mesothelioma, Seminoma, and Hepatoma. * **Options C & D (Melanophores):** Melanophores are specialized pigment-containing cells found primarily in lower vertebrates (like amphibians and fish) that allow for rapid color change. In humans, the cell of origin is the **melanocyte**, not the melanophore. **3. NEET-PG High-Yield Clinical Pearls:** * **ABCDE Criteria for Diagnosis:** **A**symmetry, **B**order irregularity, **C**olor variation, **D**iameter (>6mm), and **E**volving/Elevation [1]. * **Prognostic Indicators:** The most important prognostic factor for cutaneous melanoma is the **Breslow Thickness** (vertical depth of invasion in millimeters) [2]. * **Common Mutations:** **BRAF V600E** mutation is seen in approximately 50% of cases (Targeted therapy: Vemurafenib) [1], [2]. * **Radial vs. Vertical Growth:** The radial growth phase (horizontal spread) typically occurs first, followed by the vertical growth phase, which correlates with metastatic potential [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1151-1153. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 649-651.
Explanation: **Explanation:** **Correct Option: A. Wilms tumor** Wilms tumor (Nephroblastoma) is the most common primary renal tumor of childhood [1]. Its pathogenesis is strongly linked to the **WT1 (Wilms Tumor 1) gene**, which is located on **chromosome 11p13** [1]. Deletions or mutations in this region lead to the development of the tumor. Furthermore, the **WT2 gene**, associated with Beckwith-Wiedemann syndrome, is located on **chromosome 11p15.5**. The loss of tumor suppressor genes on chromosome 11 is a classic driver for both sporadic and syndromic Wilms tumor (e.g., WAGR syndrome) [1]. **Incorrect Options:** * **B. Neuroblastoma:** This is associated with the amplification of the **N-MYC** proto-oncogene (chromosome 2p) and deletions of the short arm of **chromosome 1**. * **C. Retinoblastoma:** This is caused by a mutation or deletion of the **RB1 gene**, which is located on **chromosome 13q14**. * **D. Osteosarcoma:** While complex genetically, it is most famously associated with mutations in the **RB1 (13q14)** and **TP53 (17p13)** genes. **High-Yield Clinical Pearls for NEET-PG:** * **WAGR Syndrome:** Wilms tumor, Aniridia, Genitourinary anomalies, and mental Retardation (associated with 11p13 deletion) [1]. * **Denys-Drash Syndrome:** Wilms tumor, Gonadal dysgenesis, and early-onset nephropathy (WT1 mutation). * **Beckwith-Wiedemann Syndrome (BWS):** Characterized by macroglossia, organomegaly, and hemihypertrophy; linked to the WT2 locus on 11p15.5 (genomic imprinting). * **Histology:** Look for the "triphasic" pattern—blastemal, stromal, and epithelial cells. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 487-488.
Nomenclature and Classification of Tumors
Practice Questions
Characteristics of Benign and Malignant Neoplasms
Practice Questions
Molecular Basis of Cancer
Practice Questions
Carcinogenesis and Carcinogens
Practice Questions
Tumor Progression and Metastasis
Practice Questions
Tumor Markers
Practice Questions
Paraneoplastic Syndromes
Practice Questions
Genetic Basis of Cancer
Practice Questions
Tumor Immunity
Practice Questions
Cancer Epidemiology and Prevention
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free